WO2016060576A1 - A liquid with cytisine for electronic cigarettes - Google Patents

A liquid with cytisine for electronic cigarettes Download PDF

Info

Publication number
WO2016060576A1
WO2016060576A1 PCT/PL2015/000168 PL2015000168W WO2016060576A1 WO 2016060576 A1 WO2016060576 A1 WO 2016060576A1 PL 2015000168 W PL2015000168 W PL 2015000168W WO 2016060576 A1 WO2016060576 A1 WO 2016060576A1
Authority
WO
WIPO (PCT)
Prior art keywords
cytisine
liquid
electronic cigarettes
nicotine
cigarettes
Prior art date
Application number
PCT/PL2015/000168
Other languages
French (fr)
Inventor
Łukasz ZALEWSKI
Piotr ZALEWSKI
Original Assignee
Zalewski Łukasz
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zalewski Łukasz filed Critical Zalewski Łukasz
Publication of WO2016060576A1 publication Critical patent/WO2016060576A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
    • A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
    • A24B15/10—Chemical features of tobacco products or tobacco substitutes
    • A24B15/16—Chemical features of tobacco products or tobacco substitutes of tobacco substitutes
    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
    • A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
    • A24B15/10—Chemical features of tobacco products or tobacco substitutes
    • A24B15/16—Chemical features of tobacco products or tobacco substitutes of tobacco substitutes
    • A24B15/167—Chemical features of tobacco products or tobacco substitutes of tobacco substitutes in liquid or vaporisable form, e.g. liquid compositions for electronic cigarettes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine

Definitions

  • the subject of the invention is a liquid with an addition of organic chemical compound with formula Cj 1H14 2O named popularly cytisine to be used in electronic cigarettes and related tobacco industry products for the purposes of substitution therapy in treatment of the nicotine addiction syndrome.
  • E-cigarettes In the current state of the art, the tobacco industry manufactures many types of liquids to be used to refill electronic cigarettes for the purpose of inhaling vapours containing nicotine.
  • E-cigarettes neither contain any combustible plant material nor generate any cigarette smoke; however, they contain nicotine as well as aromatic substances and produce nicotine-containing vapours.
  • Cytisine demonstrates effects similar to those produced by nicotine, has a stimulating effect on autonomic nervous system, mainly the respiratory centre. It stimulates also the vasomotor centre, increases secretion of adrenaline and results in an increase of blood pressure.
  • cytisine is administered in small doses in the form of tablets, as a substitute for nicotine in mitigation of nicotine cravings in the course of therapies aimed at reduction of negative effects of nicotinism. It has been proven that cytisine shows less addictive properties than nicotine and is useful in mitigation of nicotine craving symptoms.
  • the objective of the invention entitled "A liquid with cytisine for electronic cigarettes” is to provide a liquid for e-cigarettes containing an addition of extracted or synthetically obtained cytisine in a dose ranging from 0.000000001% to 99.999999999% of given liquid volume.
  • This problem has been solved by combining a liquid, solution, and/or emulsion or a mixture thereof in the amount of from 0.000000001% to 99.999999999% of given quantity of the liquefied mass with a dose of cytisine ranging from 0.000000001%) to 99.999999999% in such a way that the added cytisine increases the mass of said liquid and changes its properties, as a result of which a liquid is obtained characterised in that it contains substances other than nicotine in the amount from 0.000000001% to 99.999999999% of the liquid volume and a dose of cytisine in the amount from 0.000000001% to 99.999999999%.
  • cytisine is placed in the volume of the liquid.
  • a distinctive feature of the solution with respect to known solutions of the so-called e-liquids consists in combination of a given dose of cytisine and a liquid into a single product with properties of a liquid is such a way that, contrary to traditional liquids, it contains a measured dose of cytisine.
  • Intermediate products in the manufacturing process are: a liquid material prepared according to any formula applied by tobacco industry manufacturers and cytisine of natural origin and/or obtained synthetically, as a result of genetic modification, or a combination of these processes.
  • Cytisine is placed in glycol solution in the proportion of 90% glycol and 10% cytisine by weight as granulate, powder, emulsion, suspension, solution, deposit, material, conglomerate and/or a mixture with arbitrary proportions of these intermediate products obtained by means of chemical reactions, physical processes, genetic modifications or any combination thereof, and then subject to further processing.
  • the liquids manufactured according to the invented method when applied in vapour generators known commonly as electronic cigarettes and inhaled the form of vapours, allow to release cytisine of organic origin or obtained synthetically. Cytisine contained in the smoke of such cigarette in doses according to the invention and released from electronic cigarette gets inside, through lungs of the electronic cigarette user, to blood and produces its effect on organism of the smoking person.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Packaging Of Annular Or Rod-Shaped Articles, Wearing Apparel, Cassettes, Or The Like (AREA)

Abstract

A liquid for electronic cigarettes characterised in that in a volume of the liquefied mass it contains a dose of cytisine in the amount from 0.000000001% to 99.999999999% of the whole liquid volume.

Description

„A liquid with cytisine for electronic cigarettes"
The subject of the invention is a liquid with an addition of organic chemical compound with formula Cj 1H14 2O named popularly cytisine to be used in electronic cigarettes and related tobacco industry products for the purposes of substitution therapy in treatment of the nicotine addiction syndrome.
In the current state of the art, the tobacco industry manufactures many types of liquids to be used to refill electronic cigarettes for the purpose of inhaling vapours containing nicotine. The cigarettes, called also e-cigarettes, are usually made of plastics and house cartridges with a dose of nicotine released by a mechanism mounted inside a device imitating functional features of traditional cigarettes. E-cigarettes neither contain any combustible plant material nor generate any cigarette smoke; however, they contain nicotine as well as aromatic substances and produce nicotine-containing vapours.
It is desirable to develop effective products that could be used as a measure for the purpose of the nicotine substitution therapy. Cytisine demonstrates effects similar to those produced by nicotine, has a stimulating effect on autonomic nervous system, mainly the respiratory centre. It stimulates also the vasomotor centre, increases secretion of adrenaline and results in an increase of blood pressure.
Currently, cytisine is administered in small doses in the form of tablets, as a substitute for nicotine in mitigation of nicotine cravings in the course of therapies aimed at reduction of negative effects of nicotinism. It has been proven that cytisine shows less addictive properties than nicotine and is useful in mitigation of nicotine craving symptoms.
At present, any solutions consisting in enriching liquids for electronic cigarettes with cytisine according to the method characteristic to "a liquid with cytisine for electronic cigarettes" are not know.
The objective of the invention entitled "A liquid with cytisine for electronic cigarettes" is to provide a liquid for e-cigarettes containing an addition of extracted or synthetically obtained cytisine in a dose ranging from 0.000000001% to 99.999999999% of given liquid volume.
This problem has been solved by combining a liquid, solution, and/or emulsion or a mixture thereof in the amount of from 0.000000001% to 99.999999999% of given quantity of the liquefied mass with a dose of cytisine ranging from 0.000000001%) to 99.999999999% in such a way that the added cytisine increases the mass of said liquid and changes its properties, as a result of which a liquid is obtained characterised in that it contains substances other than nicotine in the amount from 0.000000001% to 99.999999999% of the liquid volume and a dose of cytisine in the amount from 0.000000001% to 99.999999999%.
In the technological process of manufacturing the liquid according to the invention, cytisine is placed in the volume of the liquid.
A distinctive feature of the solution with respect to known solutions of the so-called e-liquids consists in combination of a given dose of cytisine and a liquid into a single product with properties of a liquid is such a way that, contrary to traditional liquids, it contains a measured dose of cytisine. Intermediate products in the manufacturing process are: a liquid material prepared according to any formula applied by tobacco industry manufacturers and cytisine of natural origin and/or obtained synthetically, as a result of genetic modification, or a combination of these processes.
An embodiment of the solution according to the invention is described in the following as an example process of producing a unit volume of liquid with cytisine:
Cytisine is placed in glycol solution in the proportion of 90% glycol and 10% cytisine by weight as granulate, powder, emulsion, suspension, solution, deposit, material, conglomerate and/or a mixture with arbitrary proportions of these intermediate products obtained by means of chemical reactions, physical processes, genetic modifications or any combination thereof, and then subject to further processing.
The liquids manufactured according to the invented method, when applied in vapour generators known commonly as electronic cigarettes and inhaled the form of vapours, allow to release cytisine of organic origin or obtained synthetically. Cytisine contained in the smoke of such cigarette in doses according to the invention and released from electronic cigarette gets inside, through lungs of the electronic cigarette user, to blood and produces its effect on organism of the smoking person.

Claims

Patent claims
A liquid for electronic cigarettes characterised in that in a volume of the liquefied mass it contains a dose of cytisine in the amount from 0.000000001% to 99.999999999% of the whole liquid volume.
PCT/PL2015/000168 2014-10-18 2015-10-16 A liquid with cytisine for electronic cigarettes WO2016060576A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PLP.409829 2014-10-18
PL409829A PL409829A1 (en) 2014-10-18 2014-10-18 Fluid with citisine for electronic cigarettes

Publications (1)

Publication Number Publication Date
WO2016060576A1 true WO2016060576A1 (en) 2016-04-21

Family

ID=54705776

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/PL2015/000168 WO2016060576A1 (en) 2014-10-18 2015-10-16 A liquid with cytisine for electronic cigarettes

Country Status (2)

Country Link
PL (1) PL409829A1 (en)
WO (1) WO2016060576A1 (en)

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USD825102S1 (en) 2016-07-28 2018-08-07 Juul Labs, Inc. Vaporizer device with cartridge
US10045567B2 (en) 2013-12-23 2018-08-14 Juul Labs, Inc. Vaporization device systems and methods
US10045568B2 (en) 2013-12-23 2018-08-14 Juul Labs, Inc. Vaporization device systems and methods
US10058130B2 (en) 2013-12-23 2018-08-28 Juul Labs, Inc. Cartridge for use with a vaporizer device
US10076139B2 (en) 2013-12-23 2018-09-18 Juul Labs, Inc. Vaporizer apparatus
US10104915B2 (en) 2013-12-23 2018-10-23 Juul Labs, Inc. Securely attaching cartridges for vaporizer devices
US10111470B2 (en) 2013-12-23 2018-10-30 Juul Labs, Inc. Vaporizer apparatus
USD836541S1 (en) 2016-06-23 2018-12-25 Pax Labs, Inc. Charging device
USD842536S1 (en) 2016-07-28 2019-03-05 Juul Labs, Inc. Vaporizer cartridge
US10244793B2 (en) 2005-07-19 2019-04-02 Juul Labs, Inc. Devices for vaporization of a substance
US10279934B2 (en) 2013-03-15 2019-05-07 Juul Labs, Inc. Fillable vaporizer cartridge and method of filling
USD849996S1 (en) 2016-06-16 2019-05-28 Pax Labs, Inc. Vaporizer cartridge
USD851830S1 (en) 2016-06-23 2019-06-18 Pax Labs, Inc. Combined vaporizer tamp and pick tool
US10405582B2 (en) 2016-03-10 2019-09-10 Pax Labs, Inc. Vaporization device with lip sensing
US10512282B2 (en) 2014-12-05 2019-12-24 Juul Labs, Inc. Calibrated dose control
USD887632S1 (en) 2017-09-14 2020-06-16 Pax Labs, Inc. Vaporizer cartridge
US10865001B2 (en) 2016-02-11 2020-12-15 Juul Labs, Inc. Fillable vaporizer cartridge and method of filling
EP3967298A1 (en) 2020-06-30 2022-03-16 Uniwersytet Rzeszowski Aerosol composition for oral use
CN114727647A (en) * 2019-09-12 2022-07-08 阿奇维生命科学公司 Compositions comprising cytisine for treating and/or preventing addiction in a subject in need thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2011136100A (en) * 2011-08-31 2013-03-10 Александр Васильевич Иващенко PHARMACEUTICAL COMPOSITION, METHOD FOR ITS PRODUCTION AND DEVICE FOR ITS APPLICATION
EP2815741A1 (en) * 2013-06-20 2014-12-24 Changning Dekang Biotechnology Co., Ltd Oral Nicotine-Substituted Cytisine Atomized Liquid and its Preparation Method

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2011136100A (en) * 2011-08-31 2013-03-10 Александр Васильевич Иващенко PHARMACEUTICAL COMPOSITION, METHOD FOR ITS PRODUCTION AND DEVICE FOR ITS APPLICATION
EP2815741A1 (en) * 2013-06-20 2014-12-24 Changning Dekang Biotechnology Co., Ltd Oral Nicotine-Substituted Cytisine Atomized Liquid and its Preparation Method

Cited By (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10244793B2 (en) 2005-07-19 2019-04-02 Juul Labs, Inc. Devices for vaporization of a substance
US10638792B2 (en) 2013-03-15 2020-05-05 Juul Labs, Inc. Securely attaching cartridges for vaporizer devices
US10279934B2 (en) 2013-03-15 2019-05-07 Juul Labs, Inc. Fillable vaporizer cartridge and method of filling
US10104915B2 (en) 2013-12-23 2018-10-23 Juul Labs, Inc. Securely attaching cartridges for vaporizer devices
US11752283B2 (en) 2013-12-23 2023-09-12 Juul Labs, Inc. Vaporization device systems and methods
US10264823B2 (en) 2013-12-23 2019-04-23 Juul Labs, Inc. Vaporization device systems and methods
US10070669B2 (en) 2013-12-23 2018-09-11 Juul Labs, Inc. Cartridge for use with a vaporizer device
US10076139B2 (en) 2013-12-23 2018-09-18 Juul Labs, Inc. Vaporizer apparatus
US10045568B2 (en) 2013-12-23 2018-08-14 Juul Labs, Inc. Vaporization device systems and methods
US10111470B2 (en) 2013-12-23 2018-10-30 Juul Labs, Inc. Vaporizer apparatus
US10117466B2 (en) 2013-12-23 2018-11-06 Juul Labs, Inc. Vaporization device systems and methods
US10117465B2 (en) 2013-12-23 2018-11-06 Juul Labs, Inc. Vaporization device systems and methods
US10912331B2 (en) 2013-12-23 2021-02-09 Juul Labs, Inc. Vaporization device systems and methods
US10159282B2 (en) 2013-12-23 2018-12-25 Juul Labs, Inc. Cartridge for use with a vaporizer device
US10201190B2 (en) 2013-12-23 2019-02-12 Juul Labs, Inc. Cartridge for use with a vaporizer device
US10701975B2 (en) 2013-12-23 2020-07-07 Juul Labs, Inc. Vaporization device systems and methods
US10058129B2 (en) 2013-12-23 2018-08-28 Juul Labs, Inc. Vaporization device systems and methods
US10058124B2 (en) 2013-12-23 2018-08-28 Juul Labs, Inc. Vaporization device systems and methods
US10667560B2 (en) 2013-12-23 2020-06-02 Juul Labs, Inc. Vaporizer apparatus
US10058130B2 (en) 2013-12-23 2018-08-28 Juul Labs, Inc. Cartridge for use with a vaporizer device
US10045567B2 (en) 2013-12-23 2018-08-14 Juul Labs, Inc. Vaporization device systems and methods
US10512282B2 (en) 2014-12-05 2019-12-24 Juul Labs, Inc. Calibrated dose control
US10865001B2 (en) 2016-02-11 2020-12-15 Juul Labs, Inc. Fillable vaporizer cartridge and method of filling
US10405582B2 (en) 2016-03-10 2019-09-10 Pax Labs, Inc. Vaporization device with lip sensing
USD929036S1 (en) 2016-06-16 2021-08-24 Pax Labs, Inc. Vaporizer cartridge and device assembly
USD849996S1 (en) 2016-06-16 2019-05-28 Pax Labs, Inc. Vaporizer cartridge
USD913583S1 (en) 2016-06-16 2021-03-16 Pax Labs, Inc. Vaporizer device
USD836541S1 (en) 2016-06-23 2018-12-25 Pax Labs, Inc. Charging device
USD851830S1 (en) 2016-06-23 2019-06-18 Pax Labs, Inc. Combined vaporizer tamp and pick tool
USD842536S1 (en) 2016-07-28 2019-03-05 Juul Labs, Inc. Vaporizer cartridge
USD825102S1 (en) 2016-07-28 2018-08-07 Juul Labs, Inc. Vaporizer device with cartridge
USD887632S1 (en) 2017-09-14 2020-06-16 Pax Labs, Inc. Vaporizer cartridge
CN114727647A (en) * 2019-09-12 2022-07-08 阿奇维生命科学公司 Compositions comprising cytisine for treating and/or preventing addiction in a subject in need thereof
EP3967298A1 (en) 2020-06-30 2022-03-16 Uniwersytet Rzeszowski Aerosol composition for oral use

Also Published As

Publication number Publication date
PL409829A1 (en) 2016-04-25

Similar Documents

Publication Publication Date Title
WO2016060576A1 (en) A liquid with cytisine for electronic cigarettes
AU2010226152B2 (en) Tobacco-based nicotine aerosol generation system
US11517039B2 (en) Water-based vaporizable liquids, methods and systems for vaporizing same
Caponnetto et al. Electronic cigarette: a possible substitute for cigarette dependence
AU2012352395B2 (en) Device and method for simulating chemosensation of smoking
US9254002B2 (en) Tobacco solution for vaporized inhalation
GB2513061A (en) Method, composition and apparatus for functionalization of aerosols from non combustible smoking articles
MX2019006702A (en) Smart nebulizer.
CN103284319A (en) Oral cavity atomized liquid with cytosine replacing nicotine and preparation method thereof
WO2016133890A1 (en) Compositions for e-cigarettes
JP2016532691A (en) Compositions for smoking cessation and other treatments and their use
WO2016060577A1 (en) A cigarette with cytisine
De Marco et al. The electronic cigarette: potential health benefit or mere business?
Wieczorek et al. Assessment of nicotine concentration in electronic nicotine delivery system (ENDS) liquids and precision of dosing to aerosol
US20220203051A1 (en) Medix/Boost Nasal inhaler
Burnevich et al. THE ROLE OF NICOTINE REPLACEMENT THERAPY IN MODERN SOCIETY
Bhyan Electronic delivery of nicotine: help in smoking cessation or an alternative means of addiction
Majewski et al. Electronic cigarettes and their effects on human health
Hagstrom et al. Electronic Cigarettes for Smoking Cessation.
RU2237421C1 (en) Method and device for consuming gas mixtures
Gupta Weighing the Harms and Benefits of E-cigarettes
US8287922B2 (en) Vaporized Lobelia product and method of use
Mukhanova et al. Chemical evaluation of electronic ciggaretes
BRAIN THE FACTS ABOUT VAPING
Egan Role of non-nicotine tobacco constituents in the abuse liability of E-cigarettes

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15801511

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15801511

Country of ref document: EP

Kind code of ref document: A1